(Q35090804)

English

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer (English)

1 reference

Europe PubMed Central

6 August 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

12

object named as

D Ross Camidge

1 reference

Europe PubMed Central

6 August 2017

author name string

Qing Zhou

1

1 reference

Europe PubMed Central

6 August 2017

Daniel Gustafson

2

1 reference

Europe PubMed Central

6 August 2017

Sujatha Nallapareddy

3

1 reference

Europe PubMed Central

6 August 2017

Sami Diab

4

1 reference

Europe PubMed Central

6 August 2017

Stephen Leong

5

1 reference

Europe PubMed Central

6 August 2017

Karl Lewis

6

1 reference

Europe PubMed Central

6 August 2017

Lia Gore

7

1 reference

Europe PubMed Central

6 August 2017

Wells A Messersmith

8

1 reference

Europe PubMed Central

6 August 2017

Anthony M Treston

9

1 reference

Europe PubMed Central

6 August 2017

S Gail Eckhardt

10

1 reference

Europe PubMed Central

6 August 2017

Carolyn Sidor

11

1 reference

Europe PubMed Central

6 August 2017

publication date

19 January 2010

1 reference

Europe PubMed Central

6 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

6 August 2017

29

1 reference

Europe PubMed Central

6 August 2017

2

1 reference

Europe PubMed Central

6 August 2017

340-346

1 reference

Europe PubMed Central

6 August 2017

https://scigraph.springernature.com/pub.10.1007/s10637-009-9383-9

0 references

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4331064

8 July 2018

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4331064

8 July 2018

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4331064

8 July 2018

2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4331064

8 July 2018

Mechanism of action of 2-methoxyestradiol: new developments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4331064

8 July 2018

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4331064

8 July 2018

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4331064

8 July 2018

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9383-9

21 January 2018

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9383-9

21 January 2018

2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9383-9

21 January 2018

Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/20084425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Panoparticulate systems for improved drug delivery

1 reference

https://pubmed.ncbi.nlm.nih.gov/20084425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20084425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-009-9383-9

1 reference

Europe PubMed Central

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35090804&oldid=2143359576"